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Review Article on Patient Reported Outcomes in Thoracic Surgery: A New Frontier
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Abstract: Tracheobronchomalacia (TBM) is an obstructive airway disease characterized by laxity and
redundancy of the posterior membrane of the main airways leading to dynamic airway collapse during
exhalation. The gold standard for diagnosis is dynamic computed tomography (DCT) scan and dynamic
flexible bronchoscopy (DFB). Patients with complete or near-complete collapse (>90% reduction in crosssectional area) of the airway are possible candidates for surgical management. Central airway stabilization
by tracheobronchoplasty (TBP) effectively corrects malacic airways and has demonstrated significant
improvement in objective functional measures, which is often but not uniformly accompanied by equal
improvement in health-related quality of life (HRQOL) metrics. This article reviews HRQOL instruments
used to report outcomes after TBM surgery.
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Introduction
Excessive central airway collapse (ECAC) is characterized by
a dynamic flow obstruction of the airways during exhalation.
Tracheobronchomalacia (TBM) and excessive dynamic
airway collapse (EDAC) are two distinct airway pathologies
that encompass ECAC. EDAC is characterized by atrophy
of the muscular fibers in the posterior membrane of the
airway. During exhalation this lax, redundant posterior
membrane bulges anteriorly and narrows the airway. TBM
is characterized by softening and weakness of the anterior
tracheobronchial cartilaginous structures that can also lead
to posterior membrane invagination (1). Since both entities
are similar in presentation, diagnostic evaluation, and
therapeutic approach, TBM will be used to refer to both.
TBM can be classified into congenital and acquired
forms. The congenital form is predominantly observed
in the pediatric population and is beyond the scope of
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this review. The precise pathophysiological etiology of
acquired TBM is not known, however it appears in the
context of chronic airway inflammation such as in patients
with chronic obstructive pulmonary disease (COPD),
relapsing polychondritis, tracheostomy, or chronic inhaled
corticosteroid use (2-5). On presentation it can involve the
trachea alone or one or both mainstem bronchi in which
case it is considered diffuse. Progression towards severe
diffuse TBM is the fate of most patients. A bronchoscopic
surveillance study of patients with tracheomalacia and
bronchomalacia revealed a rate to severe diffuse TBM of
67% and 100% respectively over a 5-year follow-up (6,7).
Symptoms and presentation
The symptoms of TBM are nonspecific and mimic common
respiratory conditions. For this reason, TBM has been
underrecognized as a cause for airway disease and thus its
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true incidence is not known. TBM has previously been
reported in 4.5% of the general population (8). Ikeda et al.
demonstrated that over 13% of patients undergoing
evaluation for respiratory complaints were found to have
TBM (9). Patients exhibit dyspnea on exertion, persistent
cough, barking cough (due to the vibration of a redundant
collapsing posterior membrane against the anterior wall),
syncope due to coughing episodes, expiratory stridor/
wheeze, inability to clear secretions, and predisposition to
respiratory infections. High clinical suspicion is warranted
for patients that exhibit symptoms that are out of proportion
to respiratory dysfunction caused by more common diseases
such as COPD and asthma, or if symptoms fail to respond
to standard medical interventions for such illnesses. For
some, the diagnosis is only first considered after acute
presentation with respiratory failure or failure to wean from
ventilatory support as the endotracheal tube and positive
pressure stent the airways open. Others with long-term
refractory symptoms prompt further investigation with the
two established diagnostic standards: dynamic computed
tomography (DCT) and dynamic flexible bronchoscopy
(DFB). Both modalities provide visualization of airway
collapse during exhalation that can then be quantified.
The cutoff of ≥70% narrowing on forced expiration is the
recognized threshold for diagnosing TBM on DCT and
is further subclassified into mild (70% to 80%), moderate
(81% to 90%), and severe (>90%).
Indications for tracheobronchoplasty (TBP)
Initial treatment for patients suspected of TBM entails
supportive measures and maximum medical treatment of
comorbidities, such as COPD, asthma, and obstructive
sleep apnea. Part of the workup for TBM is ensuring that
symptoms cannot be reasonably explained by the presence
of other more common respiratory illnesses. Patients should
be evaluated and treated for vocal cord dysfunction and
gastroesophageal reflux disease (GERD). The prevalence
of GERD in patients with TBM has been reported at 43%
and of those, 46% report an improvement in respiratory
symptoms with maximal medical treatment or anti-reflux
surgery and require no further TBM treatment. If left
untreated, GERD may negatively impact outcomes after
TBM surgery (10). Continuous positive airway pressure
(CPAP) ventilation can improve symptoms and exercise
tolerance by stenting open airways but shows no long-term
benefit and is generally regarded as a “bridge” to surgery or
a final treatment for patients who are not surgical candidates
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(11,12).
TBP is the surgical management of TBM; it entails the
reshaping of the trachea into the more physiologic “D”
shape and splinting of the posterior wall of the airway
using a polypropylene mesh applied from the thoracic inlet
to the distal left mainstem bronchus and distal bronchus
intermedius. TBP has been described using an open right
thoracotomy approach or a minimally invasive robotic
approach. Airway stents have been used preoperatively
to predict which patients will benefit most from TBP.
A Y-shaped silicone or nitinol tracheobronchial stent is
deployed in portions of the airway that would be stabilized
by TBP. While it is reported that a significant proportion
of these patients on a “stent trial” exhibit improvement in
symptoms and a successful stent trial appears to predict
improvement after TBP, airway stents also induce mucus
plugging, increased cough, increased secretions, and are
subject to migration (13,14). These complications limit the
ability of the “stent trial” to reliably predict which patients
will respond to TBP. For this reason, stent trials are no
longer practiced by our institution.
Baseline and interval assessment
Patients with severe or complete collapse of the trachea
as evidenced on DCT or DFB should be considered for
TBP, however, objective measures of airway collapse and
pulmonary dysfunction alone are not sufficient to indicate
surgery. Previously, the cutoff for diagnosing TBM was
≥50% airway narrowing during exhalation. However, one
study revealed that 70% to 80% of healthy asymptomatic
patients exceeded >50% expiratory reduction in crosssectional area on DCT (2). Furthermore, pulmonary
function testing (PFT) via spirometry is not additive to the
diagnostic workup for TBP candidacy and the degree of
airway collapse does not correlate with spirometry measures
such as forced expiratory volume at one second (FEV1). Up
to 21% of patients with moderate to severe TBM reveal
normal flow-volume loops on spirometry (15). Gangadharan
et al. reported on 63 patients undergoing open TBP
over a 7-year period. While subjective measures showed
improvement in symptoms, there was no improvement in
FEV1; in fact almost 40% of patients had a worse FEV1
postoperatively (16). Our institution’s robotic TBP series
also revealed that 30% of patients had slightly worse
FEV1 despite high overall satisfaction score and alleviation
of symptoms with the operation (17). These results are
congruent with the findings of a study by Lee et al. that
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revealed that symptom amelioration was independent of
a decrease in air trapping as measured by CT scan, which
suggests that symptom relief is not necessarily related to
early expiratory flow-volume mechanics (18).
The 6-minute walk test (6MWT) is a simple assessment
of functional status where a patient is asked to walk as far as
they can in 6 minutes on a straight flat surface. The distance
and symptoms exhibited during the test are recorded. The
change in distance after a given intervention considered to
be clinically significant is approximately 230 feet (19). In
2011 Gangadharan et al. reported a statistically significant
improvement in 6MWT distance from an average of 987
feet preoperatively to 1,187 feet postoperatively (n=33).
While improvements in FEV1 and distance on the 6MWT
may follow an improvement in symptomatology, they do
not reliably predict efficacy of TBP preoperatively. Poor
FEV1 and lower distance on the 6MWT have however been
correlated with increased risk of postoperative pulmonary
complications (20). Spirometry in general airway disease
has only modest correlation with exercise intolerance and
functional status (21,22). Furthermore, spirometric data
correlates poorly with disease-specific health-related quality
of life (HRQOL) indices (23).
The failure of objective measures to effectively
predict improvement in symptoms after surgical
intervention demands that patients considering surgery
for TBM undergo a baseline and interval assessment of
symptomatology and quality of life (QOL). There are
several validated questionnaires for airway disease that
have been used to quantify the effect of TBM on QOL.
While recurrent infection and cough can be observed
objectively, quantifying the impact of these sequelae on
QOL is historically more challenging. Even more elusive
is the quantification of dyspnea. The American Thoracic
Society (ATS) defines dyspnea as the subjective experience
of breathing discomfort comprised of qualitatively distinct
sensations that vary in intensity. The ATS created a dyspnea
scale to assess an individual’s subjective rating of dyspnea
severity based on the magnitude of a given activity that
provokes the sensation. The scale is from 0 (breathless
with exercise) to 5 (too breathless to leave the house). The
Medical Research Council (MRC) dyspnea scale, created by
the Canadian Thoracic Society, is equivalent in both items
and scoring to that of the ATS.
The ATS and MRC dyspnea scales are simple to
administer and can even assist in predicting risk of death
from any respiratory cause in COPD patients, however they
measure only one dimension of dyspnea and the grades are
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broad, possibly rendering small but significant changes after
interventions imperceptible (24). The baseline dyspnea
index (BDI) and transitional dyspnea index (TDI) are more
discerning metrics demonstrated to be more reliable and
valid than the ATS dyspnea index (25). The BDI and TDI
are interview-administered questionnaires consisting of 24
items organized into 3 domains (functional impairment,
magnitude of task, and magnitude of effort). Each item is
graded using a Likert scale from 0 (very severe) to 4 (no
impairment); the lower the score the worse the severity of
dyspnea. A BDI collected before a given intervention can
be calculated and then compared to a TDI calculated using
the same questionnaire given post-intervention. BDI ranges
from 0 (most severe) to 12 (least severe) while TDI ranges
from –9 to +9 indicating deterioration or improvement
in severity, respectively. A change in 1 or more for TDI
is considered the minimum for significant change. The
BDI and TDI have been shown to be reproducible,
exhibit internal consistency, and has been validated against
objective measures of respiratory dysfunction as well as
other frequently used subjective instruments, such as the
Saint George’s Respiratory Questionnaire (SGRQ) (26).
The SGRQ is a well-established disease-specific QOL
instrument developed for asthma and COPD (27). The
SGRQ questionnaire consists of 14 questions with weighted
responses that yield scores from 0 to 100, with higher scores
indicating poorer health. This score is reported as a total
and broken down into the following 3 separate scores: the
symptom score addressing the frequency of symptoms, the
activity score measuring the disturbance to daily activities,
and the impact score which covers a range of psychosocial function. There is extensive data from both crosssectional and longitudinal studies that demonstrate the
validity of using SGQR to discriminate differences between
patients and evaluate changes within the same patients after
intervention, respectively. A change score of 4 units is the
minimum change considered to be a clinically significant
improvement after intervention (27,28).
Another less commonly utilized QOL instrument is the
Cough Specific Quality of Life Questionnaire (CQLQ).
Developed by French et al. in 2002, the CQLQ comprises
a list of 28 statements that patients agree or disagree with
using a 4-point Likert scale (“strongly disagree” to “strongly
agree”). The statements assess the impact that a patient’s
cough has on their daily living (e.g., “I have been completely
prevented from engaging in important activities such as
work, school, or volunteer services”). When tested on
154 chronic coughers, the CQLQ demonstrated excellent
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internal consistency, test-retest reliability, and validity in
determining impact of cough on patient’s QOL (29).
HRQOL outcomes
Ernst et al. reported QOL results of a retrospective study
on prospectively collected data between 2002 and 2009 on
COPD patients with TBM undergoing both airway stent
placement and TBP at Beth Israel Deaconess Medical
Center (BIDMC). Outcomes were stratified using the
GOLD classification of airflow limitation severity, which is
based on post-bronchodilator FEV1 as percent of predicted.
The improvement in ATS dyspnea scale (stent: –0.7, TBP:
–1.7), TDI (stent: +2.1, TBP: +3.8), and SGQR (stent: –8.2,
TBP: –27.6) were statistically significant when looking at
the combined outcomes for all GOLD stages in both the
stenting and TBP arms. Of the 94 patients that underwent
the stenting trial, 29 patients underwent TBP. When
performing a specific analysis on the 29 TBP patients,
the improvement was still seen across the aforementioned
measures but due to the small sample size this was not
statistically significant. There was no significant change in
6MWT across all GOLD stages. FEV1 increased following
both stenting and TBP in all groups except patients
with GOLD stage I but the only statistically significant
improvement in FEV1 was seen following TBP in GOLD
stage 4 patients. Of note, of the 94 patients that underwent
stenting, there was no significant difference in FEV1 and
6MWT after stent placement. In terms of QOL outcomes,
the BIDMC group reported a significant reduction
in SGQR from 74 to 46 (P<0.001) in 35 patients that
underwent pre- and post-SGQR testing after open TBP.
There was no evident correlation between GOLD stage and
SGQR reduction.
Our institution adopted the SGQR after noting the
subjective nature of outcomes during the first series of
robotic TBP. Of the 15 patients that underwent pre- and
postoperative SGQR, we observed a drop in median SGQR
score from 65.3 preoperatively to 46.2 following robotic
TBP. Of note the most improved symptom in this study
was chronic cough while the least improved was shortness
of breath. We continue to collect subjective data points and
will publish more data utilizing SGQR in the near future.
The CQLQ QOL instrument is under-utilized for TBP
but has been applied to assess symptom relief in patients
undergoing a stent trial before considering TBP. Majid
et al. reported in 2016 the results of a retrospective review
of 33 patients with severe symptomatic ECAC who
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underwent 7-day placement of uncovered self-expanding
metallic airway stents at BIDMC. The overall mean change
between pre-stent and post-stent CQLQ was –9 (P=0.015).
Thirteen of these patients subsequently underwent TBP
with a significantly improved CQLQ score at 3-month
follow-up (30). Improvement in cough appears to be a
common significant outcome after TBP across institutions
further illustrating the potential utility of the CQLQ in
assessing QOL outcomes for TBM patients in the future.
There are several limitations to the current QOL
outcome measures utilized in the treatment of TBM.
Because patients are unable to be blinded to treatment and
the QOL measures are subjective, the placebo effect can
possibly be overestimating the postoperative improvements.
As such, the durability of symptom relief requires
longitudinal follow-up. Furthermore, the study of QOL
outcomes for TBP requires larger sample sizes than have
been reported thus far. The largest TBP series have missing
QOL data for a significant portion of patients due to late
adoption of pre- and post-TBP testing thus limiting the
power of these findings. Our practice continues to collect
QOL data in all patients moving forward with the hope
of identifying preoperative scoring patterns that reliably
predict meaningful improvement for patients suffering from
this debilitating disease process. Despite these limitations,
the improvements in FEV1 and SGQR after maximal
medical management as reported in Understanding
P o t e n t i a l L o n g - t e r m I m p a c t s o n F u n c t i o n Wi t h
Tiotropium (UPLIFT) trial and Towards a Revolution in
COPD Health (TORCH) trial are a small fraction of the
reported benefits of central airway stabilization via airway
stenting and especially TBP (31,32).
Conclusions
As TBM becomes increasingly recognized in patient
populations, so does the need for a validated prediction
model for safe, efficacious intervention. The improvements
in both objective functional testing and HRQOL measures
after maximal medical management pales in comparison to
that of central airway stabilization via airway stenting and
surgery. While new techniques, such as utilization of robotic
surgery, may provide more efficacious, less morbid TBM
surgery, the identification of patients most likely to benefit
from such techniques continues to pose a challenge. The
objective measure of dynamic airway collapse with DCT
and DFB are mainstays for diagnosis but are not completely
predictive of improvement in symptomatology post-
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intervention. HRQOL instruments are not only important
for quality assurance in the treatment of a disease whose
sequelae are largely subjective, but also for research into
creating predictive models for improved patient selection
and prognostication.
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